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Abstract
Background: Type-1 cannabinoid receptors (CB1R) are enriched in the hypothalamus, particularly in the ventromedial
hypothalamic nucleus (VMH) that participates in homeostatic and behavioral functions including food intake. Although
CB1R activation modulates excitatory and inhibitory synaptic transmission in the brain, CB1R contribution to the molecular
architecture of the excitatory and inhibitory synaptic terminals in the VMH is not known. Therefore, the aim of this study was
to investigate the precise subcellular distribution of CB1R in the VMH to better understand the modulation exerted by the
endocannabinoid system on the complex brain circuitries converging into this nucleus.
Methodology/Principal Findings: Light and electron microscopy techniques were used to analyze CB1R distribution in the
VMH of CB1R-WT, CB1R-KO and conditional mutant mice bearing a selective deletion of CB1R in cortical glutamatergic (Glu-
CB1R-KO) or GABAergic neurons (GABA-CB1R-KO). At light microscopy, CB1R immunolabeling was observed in the VMH of
CB1R-WT and Glu-CB1R-KO animals, being remarkably reduced in GABA-CB1R-KO mice. In the electron microscope, CB1R
appeared in membranes of both glutamatergic and GABAergic terminals/preterminals. There was no significant difference
in the percentage of CB1R immunopositive profiles and CB1R density in terminals making asymmetric or symmetric synapses
in CB1R-WT mice. Furthermore, the proportion of CB1R immunopositive terminals/preterminals in CB1R-WT and Glu-CB1R-KO
mice was reduced in GABA-CB1R-KO mutants. CB1R density was similar in all animal conditions. Finally, the percentage of
CB1R labeled boutons making asymmetric synapses slightly decreased in Glu-CB1R-KO mutants relative to CB1R-WT mice,
indicating that CB1R was distributed in cortical and subcortical excitatory synaptic terminals.
Conclusions/Significance: Our anatomical results support the idea that the VMH is a relevant hub candidate in the
endocannabinoid-mediated modulation of the excitatory and inhibitory neurotransmission of cortical and subcortical
pathways regulating essential hypothalamic functions for the individual’s survival such as the feeding behavior.
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Introduction
The hypothalamus plays a crucial rolein regulating energy balance
and food intake [1]. The ventromedial nucleus (VMH) is placed in
the tuberal region of the hypothalamus and is associated with several
homeostatic and behavioral functions, including regulation of
appetite, energy balance, sexual behavior, anxiety, thermogenesis,
cardiovascular functions and pain [2,3]. Functionally, the dorsome-
dial VMH participates in the regulation of energy homeostasis,
whereas the ventrolateral VMH controls female reproduction [2,4].
While the large majority of VMH neurons expresses abundant
vesicular glutamate transporter VGluT2 mRNA [5–7], only weak
GAD65 mRNA and GAD67 mRNA signals are observed in this
nucleus [6,7]. The VMH is surrounded by hypothalamic
GABAergic neurons [8] and about 12% of the ventrolateral
VMH neurons are GABAergic [6].
The VMH has been proposed as a satiety nucleus that provides
a strong excitatory input to arcuate neurons, contributing to the
activation of anorexigenic neuronal pathways [9,10]. The
endocannabinoid system is implicated in endocrine regulation
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26167and energy balance. The derivatives of Cannabis sativa are well
known to regulate food intake and the endocannabinoid system
controls neuronal signaling in hypothalamic networks [11].
Although low levels of cannabinoid receptors are present in the
hypothalamic nuclei [12,13], their efficiency is higher than in
other brain regions [14]. Moreover, specific cannabinoid receptor
binding is found in several hypothalamic areas, including the
VMH, which also expresses high levels of CB1R mRNA [13].
Although the overall CB1R immunolabeling intensity is much
lower in the hypothalamus than in other brain regions, the VMH,
in particular, exhibits a moderate CB1R immunostaining [15].
The levels of the two main endocannabinoids, anandamide and
2-arachydonoylglycerol (2-AG), in the hypothalamus are higher
during fasting and lower following food intake reaching a critical
point that favors a motivational state for food intake [11,16–18].
The administration of anandamide into the VMH also stimulates
appetite in rats [19]. In contrast, both chronically-treated animals
with CB1R antagonists [11,20,21] and CB1R null mice [11,20,22]
display an anorexigenic phenotype. Furthermore, activation of
presynaptic CB1R inhibits the excitatory and inhibitory neuro-
transmission in neuronal circuits involved in eating behaviors
[11,18,23–25]. Indeed, Glu-CB1R-KO conditional mice that do
not express CB1R in neurons of cortical origin exhibit a
hypophagic phenotype after food deprivation very similar to the
full CB1R-KO. On the contrary, GABA-CB1R-KO mutants that
lack CB1R in forebrain GABAergic neurons are hyperphagic
under the same experimental conditions [26].
Taken together, it is well established that the endocannabinoid
system exerts a neuronal modulation through the activation of
presynaptic CB1R localized on both excitatory and inhibitory
pathways in distinct brain networks regulating homeostatic and
behavioral functions including food intake. In view of the
described observations that both the endocannabinoid system
and the VMH play a role in ingestive behaviors, the aim of this
study was to analyze the CB1R contribution to the molecular
architecture of the excitatory and inhibitory synaptic terminals in
the mouse VMH. For this purpose, preembedding immunocyto-
chemical techniques for light and high resolution electron
microscopy were used. Highly specific CB1R antibodies were
applied to the VMH of conditional mutant mice with a selective
deletion of CB1R mainly from cortical glutamatergic (Glu-CB1R-
KO) and mainly from forebrain GABAergic neurons (GABA-
CB1R-KO) [27,28]. Mutants with the lack of CB1R in all the cells
of the body (CB1R-KO mice) were also examined [29].
Results
Immunolocalization of CB1R in the VMH
In the light microscope, the CB1R immunoreactivity was
uniformly distributed throughout the entire VMH of CB1R-WT
(Fig. 1A) with a somehow similar appearance in the Glu-CB1R-
KO mice (Fig. 1B). At higher magnification, the pattern consisted
of abundant small immunoreactive dots densely packed within
the oval-shaped VMH (Fig. 1A’, B’). However, CB1R staining
decreased drastically in the VMH of GABA-CB1R-KO mice
(Fig. 1C), particularly in the dorsomedial part (Fig. 1C’),
suggestive of the presence of CB1R in GABAergic profiles. The
immunolabeling fully disappeared in the VMH of CB1R-KO
mice (Fig. 1D, D’).
Then, we analyzed the ultrastructural distribution of CB1Ri n
the dorsomedial region of the VMH using a preembedding
immunogold method for electron microscopy (Fig. 2). CB1R
immunoparticles were typically localized away from the active
zones on preterminal or synaptic terminal membranes making
synapses with dendrites or dendritic spines. They showed
characteristic features of excitatory (asymmetric synapses with
obvious postsynaptic densities, abundant clear and spherical
synaptic vesicles) and inhibitory (symmetric synapses with more
pleomorphic synaptic vesicles) synapses (Fig. 2A, B). 24.062.9%
and 28.967.5% of the synaptic terminals making asymmetric and
symmetric synapses, respectively, were CB1R immunopositive in
the VMH of CB1R-WT mice (Fig. 3A). In this case, CB1R density
was 0.42 immunoparticles/ mm membrane in terminals making
asymmetric synapses and 0.47 immunoparticles/ mm in terminals
making symmetric synapses (Fig. 3B). There were no statistically
significant differences in these parameters between terminals with
asymmetric or symmetric synapses in the CB1R-WT mice.
To define the contribution of cortical glutamatergic and
GABAergic synaptic terminals to the intrinsic CB1R pattern in
the VMH, conditional CB1R mutant mice lacking the receptor
either in cortical glutamatergic (Glu-CB1R-KO) or in forebrain
GABAergic neurons (GABA-CB1R-KO) were used. CB1R was still
observed in VMH axon terminals making synapses with dendritic
and spiny elements of both mutant strains (Fig. 2C-H). In Glu-
CB1R-KO mice, CB1R immunopositive terminals made asym-
metric (Fig. 2C, D) and symmetric synapses (Fig. 2E). Also, CB1R
immunonegative asymmetric synaptic terminals were found in the
Glu-CB1R-KO mutants (Fig. 2C, E), suggesting the presence of
CB1R in cortically-derived axon terminals. In GABA-CB1R-KO
tissue, CB1R immunoparticles decorated presynaptic membrane
profiles forming asymmetric (Fig. 2F, G) but not symmetric
synapses (Fig. 2H). The immunolabeling was specific as the CB1R
pattern disappeared in the VMH of CB1R-KO mice (Fig. 2I, J).
The proportion of CB1R immunopositive synaptic terminals/
preterminals in CB1R-WT (20.5%) was maintained in Glu-CB1R-
KO mice (20.8%) and reduced in the VMH of GABA-CB1R-KO
mutants (12.4%) (Fig. 4A). CB1R immunoparticles virtually
disappeared in the VMH of CB1R-KO mice (Fig. 4A). Further-
more, CB1R density in WT and both mutant animals was
estimated to be rather low (between 0.40–0.50 immunoparticles/
mm membrane, differences not statistically significant) (Fig. 4B).
We next semiquantified the CB1R immunolabeled excitatory
axonal boutons to determine the contribution of cortical axons to
the pattern of CB1R in the VMH. For this purpose, only typical
excitatory terminals with abundant clear and spherical vesicles,
forming asymmetric synapses with thick postsynaptic densities
were taken into account. In this case, 21.362.5% and 27.260.7%
of the asymmetric synapses were CB1R immunopositive in the
VMH of Glu-CB1R-KO and CB1R-WT mice, respectively
(Fig. 4C). However, this difference was not statistically significant
(x
2=0.4189, p=0.5175). Finally, the percentage of CB1R
immunolabeled asymmetric synapses was very low in CB1R-KO
mice (Fig. 4C).
Taken together, these observations indicate that CB1Ri s
localized in GABAergic as well as in cortical and subcortical
glutamatergic inputs to the VMH.
Discussion
CB1R is localized in excitatory and inhibitory presynaptic
boutons in the VMH
The main finding of this study was the localization of CB1Ri n
VMH presynaptic terminals impinging on postsynaptic dendrites
and spines of CB1R-WT, Glu-CB1R-KO and GABA-CB1R-KO
mice. Furthermore, an extensive analysis of the proportion of
immunolabeled profiles identified the contribution of CB1Rt o
GABAergic and cortical and subcortical glutamatergic inputs to
the VMH.
CB1R in VMH GABAergic and Glutamatergic Synapses
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26167The dense network of synaptic connections constitutes the
anatomical basis for the neuroendocrine and vegetative functions
regulated by the hypothalamus. The proportion of CB1R
immunolabeled synaptic terminals in the VMH of mice lacking
CB1R in neurons of cortical origin (Glu-CB1R-KO) was identical
to WT animals (,20%), indicating that CB1R probably was in
excitatory synaptic terminals of intrinsic hypothalamic neurons.
However, although the difference was not statistically significant,
the analysis of synaptic terminals forming asymmetric synapses
showed a slight decrease of glutamatergic synaptic profiles with
CB1R in Glu-CB1R-KO compared to CB1R-WT mice. Altogether,
these results indicate that CB1R localizes mostly in subcortical
excitatory axon terminals [8,22,30,31] and to a lesser extent in
excitatory synaptic boutons of cortical origin [1,8,27,31].
The absence of CB1R in forebrain GABAergic neurons (GABA-
CB1R-KO) caused a reduction of the CB1R immunolabeled
synaptic terminals (12.4%) indicating that CB1 receptors are also a
molecular component of the GABAergic axon boutons in the
VMH. For GABA-CB1R-KO mutants, DLX mice lead also to
recombination in hypothalamic dopaminergic neurons [32].
However, it is unlikely the presence of CB1R in dopaminergic
synaptic terminals in the VMH of the GABA-CB1R-KO mutants
as there is no tyrosine hydroxylase immunoreactivity in the VMH
[32]. Overall, our findings can be interpreted as for the presence of
Figure 1. CB1R immunostaining in the mouse VMH. Preembedding immunoperoxidase method for light microscopy. VMH (oval circle in A-D)
shows a moderate punctate CB1R staining in CB1R-WT (A, A’) and Glu-CB1R-KO (B, B’) mice. However, the CB1R immunoreaction product decreases in
the VMH of GABA-CB1R-KO mice, particularly in the dorsomedial part (C, C’). The CB1R pattern disappears in CB1R-KO tissue (D, D’). Framed areas in A,
B, C, D are enlarged in A’, B’, C’, D’. Scale bars: 100 mm (A, B, C, D), 50 mm (A’, B’, C’, D’).
doi:10.1371/journal.pone.0026167.g001
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intrinsic hypothalamic inhibitory pathways.
Functional significance
This investigation has demonstrated that CB1 receptors in
GABAergic and glutamatergic afferents explain the CB1R pattern
in the VMH. The density of CB1R immunoparticles was rather
low in GABAergic and glutamatergic boutons in the VMH
(,0.40–0.50 particles/ mm) as compared to the density found in
other brain regions [33,34], particularly in inhibitory synaptic
terminals [35]. However, CB1R efficiency in the activation of
GTP-binding proteins appears to be much higher in the
hypothalamus than in other brain regions [14], which may have
a functional significance. Physiologically, the identification of
CB1R in glutamatergic and GABAergic synaptic terminals in the
VMH could be regarded as a potential neuronal substrate for the
Figure 2. Ultrastructural localization of CB1R in the mouse VMH. Preembedding immunogold method for electron microscopy. A, B: In CB1R-
WT, CB1R immunoparticles (arrows) are localized on membranes of presynaptic terminals (Ter) making asymmetric (white arrowheads) and symmetric
synapses (black arrowheads) with dendritic spines (Sp) or dendrites (Den). C-E: In Glu-CB1R-KO, CB1R immunoparticles (arrows) localize to asymmetric
synaptic terminals (Ter) presumably of excitatory subcortical neurons (observe the thick postsynaptic density marked with white arrowheads in D) as
well as in inhibitory terminals (Ter) with symmetric synapses (black arrowheads in E). Notice CB1R immunonegative axon terminals (Ter) establishing
asymmetric synapses (white arrowheads in C, E) with a dendrite (Den) or a spine (Sp). F-H: In GABA-CB1R-KO, CB1R immunolabeling (arrows) is in
excitatory synaptic terminals (Ter) (see asymmetric synapses with white arrowheads in F and G) impinging on dendritic elements (Den). Observe in H
aC B 1R immunonegative synaptic terminal (Ter) making a symmetric synapse (black arrowheads) with a dendrite (Den). I, J: CB1R immunolabeling
disappears in CB1R-KO mice indicating the specificity of the CB1R antibody used in the study. Note CB1R immunonegative synaptic terminals (Ter)
making asymmetric (white arrowheads in I) and symmetric (black arrowheads in J) synapses with a dendritic spine (Sp) and a soma (Som),
respectively. Scale bars: 0.4 mm.
doi:10.1371/journal.pone.0026167.g002
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KO conditional mice exhibit a hypophagic behavior after food
deprivation very similar to the full CB1R-KO. On the contrary,
GABA-CB1R-KO mutants are hyperphagic under the same
experimental conditions [26].
As a conclusion, the VMH may be a good hub candidate in the
endocannabinoid-mediated modulation of the excitatory and
inhibitory neurotransmission regulating food intake behaviors.
These anatomical data contribute to the understanding of the




The protocols for animal care and use were approved by the
appropriate Committee at the Basque Country University
(CEBA/93/2010/GRANDESMORENO). Furthermore, the an-
imal experimental procedures were carried out in accordance with
the European Communities Council Directive of 22 July 2003
(2003/65/CE) and current Spanish regulations (Real Decreto
1201/2005, BOE 21–10–2005). Great efforts were made in order
to minimize the number and suffering of the animals used.
Figure 3. Statistical analysis of CB1R in terminals forming asymmetric and symmetric synapses in the VMH of CB1R-WT mice
processed by a preembedding immunogold method. A: 24.062.9% of synaptic terminals making asymmetric and 28.967.5% of terminals with
symmetric synapses are CB1R immunopositive. No statistically significant difference is detected (x
2=0.5946, p=0.4406, analyzed area: 2,376 mm
2). B:
CB1R density after subtraction of background labeling (0.01560.003 particles/ mm in the VMH of CB1R-KO) is pretty similar in synaptic terminals
making asymmetric or symmetric synapses (0.4260.03 and 0.4760.09 immunoparticles/ mm respectively, p=0.6553).
doi:10.1371/journal.pone.0026167.g003
Figure 4. Statistical analysis of CB1R in the mouse VMH processed by a preembedding immunogold method. A: 20.561.3% of the
synaptic terminals/preterminals are CB1R immunopositive in CB1R-WT mice. Similar proportion is in Glu-CB1R-KO (20.860.5%, x
2=0.00024, p=0.9876),
lower in GABA-CB1R-KO (12.461.2%, x
2=8.593, p=0.0034) and virtually disappears in CB1R-KO mice (3.960.6%, x
2=48.61, p,0.0001). A similar area
was analyzed for each animal condition (1,467 mm
2 in CB1R-WT; 1,562 mm
2 in Glu-CB1R-KO; 1,646 mm
2 in GABA-CB1R-KO and 1,519 mm
2 in CB1R-KO
mice). B: CB1R immunoparticle density after subtraction of background labeling (0.01560.003 particles/ mm in the VMH of CB1R-KO) is very close in
CB1R-WT (0.4960.07), Glu-CB1R-KO (0.4260.02, P=0.7000) and GABA-CB1R-KO (0.4560.03, P=0.7000) mice. C: There is no statistically significant
difference between the percentage of CB1R immunopositive asymmetric synapses in the VMH of CB1R-WT (27.260.7%) and Glu-CB1R-KO (21.362.5%,
x
2=0.4189, p=0.5175) mice. This value practically disappears in CB1R-KO mice (2.962.9%, x
2=15.47, p,0.0001). A similar area was analyzed for each
animal condition (1,352 mm
2 in CB1R-WT; 1,547 mm
2 in Glu-CB1R-KO and 1,274 mm
2 in CB1R-KO mice).
doi:10.1371/journal.pone.0026167.g004
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Mutant animals were obtained and genotyped as previously
described [26,27,29]. CB1R-KO mice were generated and
genotyped as described [29]. Conditional CB1R mutant mice were
obtained by crossing the respective Cre-expressing mouse line with
CB1
f/f mice [36], using a three-step breeding protocol [27].
Generation of CB1
f/f; NEX-Cre mice (here Glu-CB1R-
KO). CB1
f/f; NEX-Cre mice were obtained by crossing CB1
f/f
with NEX-Cre mice [37,38]. The helix-loop-helix transcription
factor NEX is a marker of embryonic neuronal progenitors, which
will develop into mature cortical glutamatergic neurons [39],
whereas, in the adult brain, NEX is expressed in mature
glutamatergic cortical neurons, but not in cortical GABAergic
interneurons and to a much lesser extent in subcortical regions
[40]. Cre expression under the control of the regulatory sequences
of NEX in transgenic mice (NEX-Cre mice) as generated by
knock-in into the NEX locus, leads to the specific deletion of
‘‘floxed’’ alleles in forebrain neurons [37].
Generation of CB1
f/f; Dlx5/6-Cre mice (here GABA-CB1R-
KO). Transgenic mice (Dlx5/6-Cre) were produced as previously
described [41]. Dlx5/6-Cre mice were crossed with CB1
f/f mice to
obtain CB1
f/f; Dlx5/6-Cre mice [27]. Dlx5/Dlx6 genes are homeobox
genes that are expressed in differentiating and migrating forebrain
GABAergic neurons during embryonic development [42]. Thus,
expression of Cre recombinase under the control of the regulatory
sequences of Dlx5/Dlx6 genes is expected to drive recombination of
loxP sites in GABAergic neurons [27].
Animal treatment
12 wild-type, Glu-CB1R-KO, GABA-CB1R-KO and CB1R-KO
mice (3 of each condition) were used in this study. Mice were
deeply anesthetized by intraperitoneal injection of ketamine/
xylazine (80/10 mg/kg body weight) and were transcardially
perfused at room temperature (RT, 20–25uC) with phosphate-
buffered saline (PBS 0.1M, pH 7.4) for 20 seconds, followed by the
fixative solution made up of 4% formaldehyde (freshly depoly-
merized from paraformaldehyde), 0.2% picric acid and 0.1%
glutaraldehyde in phosphate buffer (PB 0.1 M, pH 7.4) for 10–15
minutes. Then, brains were removed from the skull and postfixed
in the fixative solution for approximately one week at 4uC.
Afterwards, brains were stored at 4uC in 1:10 diluted fixative
solution until used.
CB1R immunocytochemistry for light microscopy
Coronal hypothalamic sections were cut at 50 mmi na
vibratome and collected in 0.1 M PB at RT. Sections were
preincubated in a blocking solution of 10% bovine serum albumin
(BSA), 0.1% sodium azide and 0.5% triton X-100 prepared in
Tris-HCl buffered saline (TBS 1X, pH 7.4) for 30 minutes at RT.
Then, they were incubated in a primary polyclonal goat anti-
CB1R antibody (2 mg/ml, Frontier Science co. Ltd, 1–777–12,
Shinko-nishi, Ishikari, Hokkaido, Japan) prepared in the blocking
solution, on a shaker for 2 days at 4uC. The CB1R antibody
recognizes 31 aminoacids of the C-terminus part (NM007726) of
the mouse CB1R. After several washes in 1% BSA and 0.5% triton
X-100 in TBS, tissue sections were incubated in a secondary
biotinylated horse anti-goat IgG (1:200, Vector Laboratories,
Burlingame, CA, USA) prepared in the washing solution for
1 hour on a shaker at RT. The VMH sections were washed in the
washing solution described above and processed by a conventional
avidin-biotin peroxidase complex method (ABC, Elite, Vector
Laboratories, Burlingame, CA, USA). Tissue was incubated in the
avidin-biotin complex (1:50) prepared in the washing solution for
1 hour at RT. Then, sections were washed and incubated with
0.05% diaminobenzidine in 0.1 M PB with 0.5% triton-X100 and
using 0.01% hydrogen peroxide as a cromogen, for 5 minutes at
RT. Finally, tissue was mounted, dehydrated in graded alcohols
(50u,7 0 u,9 6 u, 100u) to xylol and coverslipped with DPX. Sections
were observed and photographed with a light microscope Zeiss
Axiophot. Figure compositions were made at 300 dots per inch
(dpi). Labeling and minor adjustments in contrast and brightness
were made using Adobe Photoshop (CS, Adobe Systems, San Jose,
CA, USA).
Preembedding immunogold method for electron
microscopy
Coronal hypothalamic vibrosections were cut at 50 mm and
collected in 0.1 M PB at RT. Sections were preincubated in a
blocking solution of 10% BSA, 0.1% sodium azide and 0.02%
saponin in TBS for 30 minutes at RT. Then, they were incubated in
a primary polyclonal goat anti-CB1R antibody (2 mg/ml, Frontier
Science co. Ltd, 1–777–12, Shinko-nishi, Ishikari, Hokkaido, Japan)
prepared in the blocking solution but with 0.04% saponin, on a
shaker for 2 days at 4uC. After several washes with 1% BSA in TBS,
tissue sectionswereincubated ina secondary 1.4 nm nano-gold anti-
goat antibody (1:100, Fab’ fragment, Nanoprobes Inc., Yaphank,
NY, USA) prepared inthe same solution as the primary antibody for
3 hours on a shaker at RT. Then, tissue was washed overnight at
4uCandpostfixedin1%glutaraldehydefor10minutes.Afterseveral
washes in double distilled water, gold particles were silver-intensified
with a HQ Silver Kit (Nanoprobes Inc., Yaphank, NY, USA) for 12
minutes in the dark. Then, tissue was extensively washed in double
distilled water and in 0.1 M PB and osmicated in 1% osmium
tetroxide for 20 minutes. After washing in 0.1 M PB, sections were
dehydrated in graded alcohols (50u,7 0 u,9 6 u,1 0 0 u) to propylene
oxide and embedded in Epon resin 812. 80 nm ultrathin sections
were collected on mesh nickel grids, stained with lead citrate for 20
minutes and examined in a PHILIPS EM208S electron microscope.
Tissue preparations were photographed by using a digital camera
coupled to the electron microscope. Figure compositions were made
at 300 dots per inch (dpi). Labeling and minor adjustments in
contrast and brightness were made using Adobe Photoshop (CS,
Adobe Systems, San Jose, CA, USA).
Specificity of the immunostainings was assessed by incubation of
the CB1R antibody in CB1R-KO VMH tissue in the same
conditions as above.
Statistical analysis of CB1R in the VMH
50-mm-thick hypothalamic sections from each animal condition
(n=3 each) showing good and reproducible silver-intensified gold
particles were cut at 80 nm. Image-J (version 1.43 m, NIH, USA)
was used to measure the membrane length. Electron micrographs
(18,000–28,000X) were taken from grids (132 mm side) containing
silver-intensified gold particles; all of them showed a similar
labeling intensity indicating that selected areas were at the same
depth. Furthermore, to avoid false negatives, only ultrathin
sections in the first 1.5 mm from the surface of the tissue block
were examined. Positive labeling was considered if at least one
immunoparticle was within approximately 30 nm from the
plasmalemma. Metal particles on synaptic membranes were
visualized and counted.
Percentages of CB1R positive profiles and density of immuno-
particles were analyzed and displayed as mean 6 S.E.M. using a
statistical softwarepackage(GraphPad Prism4,GraphPad Software
Inc, San Diego, USA). Group differences were compared by chi-
square test, p,0.05 (percentages of CB1R positive profiles) and
Mann Whitney test, p,0.05 (CB1R density).
CB1R in VMH GABAergic and Glutamatergic Synapses
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